AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy

Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are important because many patients do not live long enough to receive a second-line cancer therapy. The post AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line…

Read More

Robots and Health

An interesting finding from Liu, Wang, Jin and Lu (2025): While the labor market effects of industrial robots have been extensively studied, their broader health implications, particularly on chronic diseases, remain unexplored. This study fills this gap by linking China’s national-industry robot adoption data to individual health records from the China Health and Nutrition Survey…

Read More

How Much More Would People Pay in Premiums if the ACA’s Enhanced Subsidies Expired

Enhanced Affordable Care Act (ACA) subsidies lower premium payments for ACA Marketplace coverage by boosting existing ACA subsidies and making some people newly eligible. Enrollees across incomes benefit from these subsidies. For example, low-income enrollees (making up to 150% of the poverty level) became eligible for free or nearly free coverage. Those earning over four…More

Read More

Claims Denials and Appeals in ACA Marketplace Plans in 2023

This brief analyzes federal transparency data released by the Centers for Medicare and Medicaid Services (CMS) on claims denials and appeals for non-group qualified health plans (QHPs) offered on HealthCare.gov in 2023. It finds that HealthCare.gov insurers denied nearly one out of every five claims (19%) submitted for in-network services. Information about the reasons for…

Read More

Chronic Lung Disease in Medical Literature for More Than 200 Years Finally Has Its First Drug

Insmed’s Brinsupri is the first drug specifically approved for treating non-cystic fibrosis bronchiectasis, a progressive and potentially fatal lung disorder. The drug, licensed from AstraZeneca, inhibits activation of neutrophils, white blood cells that play a role in inflammatory and immune responses. The post Chronic Lung Disease in Medical Literature for More Than 200 Years Finally…

Read More